Trial NCT03026166

View at ClinicalTrials.gov 
Org. Study IDs: M16-300
Secondary IDs: 2016-003686-26

Last trial update was posted on 2020-07-17

MeSH Interventions

Ipilimumab Nivolumab Rovalpituzumab tesirine

MeSH Conditions

Lung Neoplasms Small Cell Lung Carcinoma

Other Conditions

Small Cell Lung Cancer

Stopping Reasons

Enrollment was stopped after the dose-limiting toxicity (DLT) evaluation phase of Cohort 2.

Limitations And Caveats

N/A

Result Publications

N/A

Annotations

Category Annotations
No annotators decided on categories yet

Intervention Annotations
# Outdated Intervention Condition
Name Route DrugBank ID